Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Core Viewpoint - Galecto, Inc. has granted non-qualified stock options to a new employee as part of its 2022 Inducement Plan, which is a strategic move to attract talent in the biotechnology sector [1][2]. Company Overview - Galecto, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for hematological cancers, with a specific emphasis on mutant calreticulin-driven myeloproliferative neoplasms [3]. - The company is preparing to submit an Investigational New Drug (IND) application for its lead asset, DMR-001, which targets mut-CALR and is expected to be filed in mid-2026 [3]. - Galecto's pipeline also includes GB3226, a first-in-class preclinical dual inhibitor aimed at treating various genetic subsets of acute myeloid leukemia (AML) [3].